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Abstract
Background: Despite the benefits of malaria diagnosis, most presumed malaria episodes are never tested. A primary reason
is the absence of diagnostic tests in retail establishments, where many patients seek care. Malaria rapid diagnostic tests
(RDTs) in drug shops hold promise for guiding appropriate treatment. However, retail providers generally lack awareness of
RDTs and training to administer them. Further, unsubsidized RDTs may be unaffordable to patients and unattractive to
retailers. This paper reports results from an intervention study testing the feasibility of RDT distribution in Ugandan drug
shops.
Methods and Findings: 92 drug shops in 58 villages were offered subsidized RDTs for sale after completing training. Data
on RDT purchases, storage, administration and disposal were collected, and samples were sent for quality testing.
Household surveys were conducted to capture treatment outcomes. Estimated daily RDT sales varied substantially across
shops, from zero to 8.46 RDTs per days. Overall compliance with storage, treatment and disposal guidelines was excellent.
All RDTs (100%) collected from shops passed quality testing. The median price charged for RDTs was 1000USH ($0.40),
corresponding to a 100% markup, and the same price as blood slides in local health clinics. RDTs affected treatment
decisions. RDT-positive patients were 23 percentage points more likely to buy Artemisinin Combination Therapies (ACTs)
(p=.005) and 33.1 percentage points more likely to buy other antimalarials (p,.001) than RDT-negative patients, and were
5.6 percentage points more likely to buy ACTs (p=.05) and 31.4 percentage points more likely to buy other antimalarials
(p,.001) than those not tested at all.
Conclusions: Despite some heterogeneity, shops demonstrated a desire to stock RDTs and use them to guide treatment
recommendations. Most shops stored, administered and disposed of RDTs properly and charged mark-ups similar to those
charged on common medicines. Results from this study suggest that distributing RDTs through the retail sector is feasible
and can reduce inappropriate treatment for suspected malaria.
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Introduction
The importance of scaling up parasitological confirmation of
malaria for effective and efficient malaria control programs is
widely recognized [1,2]. Efforts to increase access to malaria
diagnosis have been fueled by a growing awareness of high levels
of inappropriate malaria treatment and of the negative conse-
quences of treating non-malarial illnesses with antimalarials.
Reyburn et al. [3] find that, among Tanzanian inpatients admitted
to the hospital for severe malaria, the case fatality rate was higher
for those who were actually malaria-negative than for those who
were malaria-positive based on blood film microscopy. In general,
there is substantial symptom overlap between malaria and other
common illnesses caused by viral and bacterial infections [4,5].
High rates of presumptive treatment with antimalarials can also
result in a substantial waste of public and private resources –
particularly in the presence of subsidies for expensive treatments
such as ACT [6,7,8,9,10,11,12]. Presumptive treatment can also
accelerate the emergence of parasite resistance [13,14,15]. Finally,
the absence of widespread parasitological confirmation of malaria
has been likened to ‘‘working with a blindfold’’ in that it is difficult
to know where to target resources and how to track progress in
malaria control programs [14,16,17,18]. For all these reasons, the
WHO now recommends parasitological confirmation of malaria
whenever possible in its malaria treatment guidelines [1].
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malaria (RDTs) have substantially increased the ability to make
diagnostic confirmation available at all levels of the health system,
including the formal and informal private sector and community-
based care [16,17,18,19,20]. RDTs have been shown to be highly
sensitive and specific and to outperform microscopy in field
conditions [21,22,23,24]. Universal access to malaria diagnosis,
however, is unlikely to be achievable through scale up of RDTs in
the formal public health system alone. This is because many
patients suspecting malaria seek treatment outside of the public
sector, where facilities are often distant, suffer frequent stock outs
and have limited operating hours [25,26,27,28].
There has been considerable discussion around whether and
how increasing the availability of RDTs in the retail sector should
be pursued in connection to (or perhaps instead of) a subsidy on
ACTs, such as the one implemented through the pilot Affordable
Medicines Facility for Malaria [6,7,29,30]. In the context of ACT
programs, scaling up RDTs offers the opportunity to significantly
improve the targeting of public funds. While RDTs have been
distributed in Cambodia’s retail sector since 2002 [28], little is
known regarding the quality of implementation, including how
well the RDTs are being stored by shops, how successfully shops
are performing them, and the extent to which the tests are being
used to guide treatment behavior. If RDT negative results are
commonly ignored and antimalarials are prescribed anyway, or if
antibiotics are prescribed at very high rates to those testing
negative, the cost-effectiveness and public health impact of RDTs
could be compromised [31,32,33]. Beyond uncertainty over the
operational feasibility of RDT scale up and the use of RDTs to
guide treatment recommendations, concern has been expressed
over whether retail sector providers would have an economic
incentive to promote and sell RDTs to their clients, considering
the substantial share of revenue that is generated from antima-
larials [11,34].
The most extensive evidence on the feasibility of RDTs in the
retail sector outside this study comes from the experience of
Cambodia, where RDTs (Paracheck, brand name ‘‘Malacheck’’)
have been socially-marketed and available in drug shops since
2002 [28]. Population Services International manages the training
of shops and distribution of the RDTs, selling the tests for $0.05 to
wholesalers with a recommended retail price of $0.24. While
significant bottlenecks in supply chain procurement were encoun-
tered, there is evidence that RDTs have become increasingly
available in shops since the roll-out of this program [28].
Unfortunately, there is no evidence on how well the RDTs are
stored by shops, on how successfully shops administer them, or on
the extent to which the tests are used to guide treatment behavior.
No study has analyzed the feasibility of similar programs in the
sub-Saharan African context.
To explore the feasibility of retail sector RDT distribution in
Uganda subsidized RDTs were made available to licensed drug
shops in six Ugandan districtss upon successful completion of an
RDT training program. RDT training uptake, sales and final
prices to patients were monitored. RDTs were sold to shops
through a Ugandan wholesaler. he intervention was designed to
replicate an unrestricted market at the retail level. Shops were free
to choose whether to stock RDTs and sell them to clients, free to
choose the price at which the RDTs were sold and free to make
treatment recommendations as they wished. The primary objec-
tive of this study was to assess the overall feasibility of RDT
distribution in the retail sector from a supply side perspective, i.e.
to assess both the willingness of shops to distribute RDTs and the
overall quality of the resulting test administration.
Methods
1. Ethics Statement
Ethical approval for this study was given by the Harvard School
of Public Health (IRB Protocol # P19371-105) and the Uganda
National Council for Science and Technology (Protocol #
HS805). Written consent from the female head of household
was obtained at baseline for the household surveys. This included
consent to be followed up with on a monthly basis and consent to
speak with another caregiver in the household if the primary
female caregiver was absent for an extended period of time.
Verbal consent was obtained at each follow-up household survey.
Written consent to participate in the study was obtained from drug
shop owners at baseline unless the owner lived in a distant district
in which case verbal consent was obtained by phone from the shop
owner and written consent was obtained from the primary shop
attendant.
2. Study Context and Population
Malaria is responsible for 30–50% of outpatient visits and 9–
14% of inpatient deaths in Uganda, making it one of the most
serious health problems faced by the population [35]. Malaria
prevalence in children under 5 in Uganda ranges from 7.4% in
Kampala to 80% in the mid-Northern region [27]. This study
takes place in districts in the mid-Eastern and Northeastern
regions, where prevalence among children is 40–55%. Ugandan
Ministry of Health guidelines recommend parasitological confir-
mation of suspected malaria prior to treatment, but presumptive
treatment is still the norm, especially in rural health clinics [36].
Ugandans commonly seek treatment for malaria in the retail
sector [25,26,27], with outlets ranging from small, informal,
unlicensed shops and vendors to licensed pharmacies (with the
latter present mostly in urban areas).
The study was conducted in six districts in Eastern Uganda:
Budaka, Bukedea, Kibuku, Kumi, Ngora and Pallisa. The area is
mostly rural, with a total estimated population of 1.3 million in
2011. Malaria is endemic in the region, with transmission rates of
more than 100 infective bites per person per year [27]. Peak
malaria incidence in Uganda corresponds to the two rainy seasons,
one between March and May and the other between September
and December.
3. Procedures
Pretesting. Piloting took place between November and
January 2010, and the main study period occurred between
March 2011 (baseline) and April 2012 (endline). This paper
focuses on the first six months after RDT training, covering the
period from June to December 2011. Analysis is restricted to the
first six months since additional interventions that could affect
RDT distribution were introduced after this period and will be
explored future work. Uganda is an AMFm pilot country, and the
first subsidized ACTs arrived in Uganda in late April 2011.
Sample Selection. The sampling frame for the study
included all villages with at least one drug shop licensed and
registered with the Ministry of Health in the six study districts. Out
of the 92 villages listed, 67 villages were randomly selected for the
RDT program. A total of 108 registered shops in these 67 villages
were invited to participate in the RDT training. In order to
monitor treatment behavior at the household level, all households
in the selected villages were listed and 30 households from each
village randomly selected for household surveys.
Randomization. Both the selection of the 67 villages and the
households within each of the villages were done using a simple
random number draw generated by Stata Version 11.0 SE (Stata
Malaria Diagnosis in the African Retail Sector
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distribution of the selected villages within the six study districts.
Data collection. Drug shops were visited for an initial
baseline survey and then once per month on an unannounced
day by trained project staff for monitoring of RDT storage,
administration and disposal. If none of the trained shop staff were
present on the day of the visit, study staff made two additional
attempts to complete the monitoring module in that month. At the
time of the visit, information was recorded on how many RDTs (if
any) the shop had purchased and administered in the past month,
how many of the administered tests were positive and negative and
what they were currently charging patients for an RDT. At the
time of the monitoring visit, a free RDT was offered to a customer
visiting the shop (or a volunteering passerby on the street if there
were no customers in the shop) and a 17-point monitoring
checklist was completed that covered whether shop attendant
administered and read the RDT properly and disposed of sharps
and other waste properly. The monitoring checklist also included
items about how the RDTs were stored and the working surface
on which RDTs were administered. Every three months
(September 2011 and December 2011), four unused RDTs were
collected from shops’ current stock and sent for lot testing at the
Foundation for Innovative Diagnostics (FIND) laboratory at the
Pasteur Institute of Cambodia in order to ensure that the quality of
the tests was not compromised. Lot testing involved measuring
detection rates in parasite positive samples of 200 and 2000
parasites per micro-liter of blood, and measuring detection rates in
parasite negative samples. As the RDTs distributed in the study
arrived in Uganda in October 2010 (and were manufactured in
September 2010) the tests had been in Uganda for 11 months at
the time of the first round of lot testing and 14 months at the
second round.
Households were visited for a baseline survey collecting data on
demographic characteristics, assets, and malaria knowledge and
treatment seeking behavior. After the initial visit, households were
visited once per month for follow-up surveys, designed to capture
illness episodes and how they were resolved. If respondents
affirmed that someone in the household had been sick in the past
month, an illness module was completed that collected detailed
information on the type and duration of the health problem, type
of health service accessed, medication taken, costs of medication
and testing and whether blood-test-based diagnosis was conducted.
Equipment and Training. The RDTs used in this study
were the Care Start Malaria HRP2 Pf test, manufactured by Access
Bio. The most recent WHO/FIND report on RDT quality found
that this test has a panel detection score of 98.7% and a total false
positive rate of 2.4% [37]. We adapted the RDT training manual
developed for training community health workers and medical
professionals in rural health clinics in ‘‘generic Pf tests’’ by FIND,
the World Health Organization (WHO)[38] based on initial field
trials in Zambia [39][40]. The manual was adapted to refer to the
specific procedure for administering the CareStart test. The
manual (and the training lessons) explained how RDTs work, how
to administer them safely and how to read the results, and
included pictorial instructions and exercises. It also reviewed signs
of severe illness and when clients and children should be referred
to a higher level health facility immediately. Participants were
given only very broad recommendations on treatment and were
not given any specific instructions or direction on when to perform
the tests. The main recommendation was to ‘‘proceed as you
would normally with a client you thought had [did not have]
Figure 1. Study villages.
doi:10.1371/journal.pone.0048296.g001
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suggested. The objective was to train drug shop personnel only
about how RDTs work and how to use them, and to observe
whether and how shops chose to integrate them into their normal
practice. The trainings were facilitated by trainers from the
Ugandan Ministry of Health. The first day of training involved
‘‘classroom’’ instruction. The second day of training took place in
a local health facility and provided the participants with practical
experience administering RDTs to patients. Upon successful
completion of the training, participants were given a free starter
box of 40 RDTs and a sharps disposal box. Shops were also
provided with free gloves for all RDTs purchased throughout the
study.
RDT Distribution and Pricing/Markups. RDTs were
purchased and imported for just under US$0.70 per test by the
study. Upon arrival in Uganda, a sample of the procured RDTs
was sent for lot testing at the Pasteur Institute of Cambodia. All
sampled RDTs passed lot testing prior to the start of the study.
The RDTs were sold to one of the main drug wholesalers (Abacus)
in Kampala at a price of USH 300 (US$0.12) per RDT. A
contractual agreement ensured that the RDTs would be distrib-
uted from Abacus’s regional wholesale pharmacy in the city of
Mbale, and sales would be restricted to study shops that had
successfully completed the RDT training. To make sure this rule
was enforced, sales staff had to enter the name of the purchaser as
well as the quantity sold into a spreadsheet, which was collected by
project staff on a bi-monthly basis. The agreed price at which
shops were allowed to purchase RDTs from the wholesale
pharmacy was USH 500 (US$0.20). In return for the USH 200
(US$0.08) margin per RDT, the wholesaler stored the RDTs in
their main warehouse in Kampala, kept track of sales and
restocked the regional pharmacy in Mbale as needed.
Additional Data Collection. In order to monitor shop
behavior, the sales data reported by shops during the monthly
monitoring visit was complemented with administrative records
from the wholesale distributor in Mbale. Finally, a baseline survey
was administered to drug shop owners (or, if the owner lived
outside of the district, primary shop attendants), with basic
questions about shop characteristics, questions about medication
stocking, pricing and markups were asked, as well as questions
about perceptions and beliefs about malaria treatment and
diagnosis.
4. Data Entry and Analysis
Data was entered using the CSPro 4.0 package. All analysis was
conducted using Stata Version 11.0 SE (Stata Corporation,
College Station, TX).
Results
1. Program Coverage
Using the official drug shop list provided by the District
Assistant Drug Inspector, a total of 108 shops in 67 villages were
identified in the study districts and invited to the training. 85%
(n=92) of invited shops attended and successfully completed the
training; 15 shops had either closed or decided not to attend the
training, and one shop failed the training. Out of the targeted 67
villages, RDTs were available through at least one shop in 58
villages (village level coverage 87%).
2. Characteristics of Trained Shops
Tables 1 and 2 show descriptive statistics for the 92 successfully
trained shops as collected during the shop baseline interview. The
average shop had been in operation for about 6.75 years and had
only one employee in addition to the owner. Typically one person
working at the shop was trained as a nurse or nursing assistant;
only 12% of shops had a trained pharmacist actively working at
the shop. As in most areas of Uganda, the density of drug shops is
high, with enrolled drug shops on average reporting 5.6 other
shops (most of which are likely unregistered/unlicensed) within a
30 minute walking distance. On average, drug shops report the
nearest public health facility to be just over 30 minutes walking
distance away. Most shops (87%) primarily stock from wholesalers
in Mbale, which is the closest city. More nearby and smaller urban
areas like Kumi are typically used for smaller purchases.
3. RDT Uptake and Volumes
Table 3 summarizes the total number of RDTs purchased by
shops between July and December 2011. These are purchases
made subsequent to the free box of 40 RDTs given to shops after
successful completion of training. Over this six-month period, a
total of 13,240 RDTs were sold, which corresponds to an average
of about 2200 RDTs per month. As most shops are open 26 days
per month on average, this corresponds to a rate of 85 RDTs per
day, or about one RDT per day per shop. If the 40 RDTs given at
training are included, this corresponds to 109 RDTs per day, or
1.2 RDTs per day per shop. Out of the 92 trained shops, 56 shops
(61%) restocked at least once over the six-month period. As Table 3
shows, the variance between shops was large, with many shops
selling small quantities of RDTs, and the largest six shops
distributing over 40% of total volume.
Table 4 and Figure 2 show the number of RDTs purchased
each month by trained shops from the wholesaler based on the
wholesaler’s administrative data. Restocking was highest in
October, with a volume of 2600 RDTs, and lowest in July and
December, with sales below 2000 tests. The incidence of fever over
this period (based on the household survey data) fluctuated
between 0.146 and 0.192 cases per person per month, with the
highest levels in September and October, and lowest in August
and November.
4. RDT Pricing
Pricing information was collected both through the monthly
shop monitoring visits and the household surveys. In both surveys,
the median price was USH 1000 (US$ 0.40), which corresponds to
a 100% markup for shops. It is possible that shops were charging
this price to compete with local private clinics, which were
charging USH 1000 for blood slide microscopy (see Table 5). Very
few shops appear to have provided testing for free; the highest
price households reported to pay was USH 5000 (US$ 2.00).
Mark-ups for RDTs were in the mid-range of markups for other
products at program shops. Based on information collected in our
baseline survey with shop owners, participating shops charged on
average a 140% markup on anti-pyretics, 108% markup on
Table 1. Characteristics of Trained Shops.
Variable Mean (S.D.)
Months in operation 80.95 (59.25)
Number of employees (excluding owner) 0.99 (0.72)
Drug shops within 30 min walk 5.62 (3.61)
Minutes to walk to nearest public facility 34.28 (31.79)
Distance to Mbale in kilometers 42.48 (15.01)
doi:10.1371/journal.pone.0048296.t001
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ACT antimalarials.
5. Program Compliance
Tables 6 and 7 illustrate that compliance with the treatment,
storage and waste management protocols was very high overall.
Compliance was particularly high with respect to storage and
waste management: in 312 monitoring visits conducted between
August and December 2011, overall compliance was very high,
with only minor violations observed during the first rounds of the
monitoring. As Table 6 illustrates, similarly positive results were
found for the actual administration of the RDTs. On nearly all
domains, compliance was over 95%. The only steps that resulted
in non-compliance rates greater than 10% were: 1) the checking of
the expiry date (most shops stated that they checked this at the
time of purchase and thus did not check again at the time of
administration), 2) the collection of the correct amount of blood
with the pipette, and 3) the writing of the patient’s name on the
cassette. No single step in the administration process resulted in
non-compliance rates greater than 17%. We also tracked
compliance over time. As shown in Table 8, compliance improved
slightly over time, with an average number of 0.79 specific tasks
(out of the 17 tasks listed below) missed in August and an average
number of 0.31 tasks missed in December.
6. RDT Quality
Four tests from each of 61 shops (n=244) and 55 shops
(n=220) were sent for quality testing in rounds 1 and 2,
respectively. 100% of the RDTs passed lot testing (both parasite
positive and parasite negative detection) in each round.
7. Adherence to Test Results
Figure 3 shows medication purchases by diagnosis as reported
by households visiting shops trained in the study between July and
December 2011. Households reported a total of 2,037 visits and
307 of those visits involved the purchase of an RDT. Among
RDTs purchased, 89% (247/307) reported a positive test result.
Among those testing positive, 32% purchased an ACT, 23
percentage points higher than those testing negative (p=.005)
and 5.6 percentage points higher than those not getting tested at
all (p=.05). 66.4% of RDT-positive patients purchased another
antimalarial of some kind, 33.1 percentage points higher than
those testing negative (p,.001) and 31.4 percentage points higher
than those not being tested at all (p,.001). There were no
significant differences in rates of antibiotic purchases between
RDT-positive patients and RDT-negative patients or between
RDT-positive patients and patients who were not tested. Many
patients bought several medications.
Table 2. Characteristics of Trained Shops.
Variable N %
Most educated staff: nurse 36 39.13
Most educated staff: nurse assistant
) 23 25.00
Most educated staff: pharmacist
) 10 11.96
Most educated staff: other 21 23.91
Stocks from Mbale
a) 79 86.96
Stocks from Kumi
a) 24 26.09
Stocks from other locations
a) 24 26.09
Notes:
a)Categories are not exclusive; some shops report to stock from multiple
locations.
doi:10.1371/journal.pone.0048296.t002
Table 3. Restocking Distribution Over a Six Month Period.
RDTs Bought Frequency % of shops Cumulative Average RDTs per Day*
0 36 39.1% 39.1% 0.00
40 16 17.4% 56.5% 0.26
80 10 10.9% 67.4% 0.51
120 7 7.6% 75.0% 0.77
160 4 4.3% 79.3% 1.03
200 1 1.1% 80.4% 1.28
240 1 1.1% 81.5% 1.54
280 2 2.2% 83.7% 1.79
320 1 1.1% 84.8% 2.05
360 2 2.2% 87.0% 2.31
400 3 3.3% 90.2% 2.56
440 2 2.2% 92.4% 2.82
480 1 1.1% 93.5% 3.08
760 3 3.3% 96.7% 4.87
960 1 1.1% 97.8% 6.15
1160 1 1.1% 98.9% 7.44
1320 1 1.1% 100.0% 8.46
Note: RDTs were sold in boxes of 40, and therefore, total sales are in multiples of 40.
*Assumes shop is open 26 days per month.
doi:10.1371/journal.pone.0048296.t003
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If the program evaluated here was scaled up exactly as is
(including the extensive monitoring operations) to 500 shops, the
estimated cost per RDT purchased and used would be US$1.59.
This includes the subsidy to the manufacturer price, shipping and
handling to get the RDTs to the distributor, the costs of training
and supplying the drug shops with equipment needed to
administer the tests (including gloves), the costs of monitoring
the drug shops to be sure that they administer and handle the tests
properly, and the administrative overhead for the project.
Intermediate cost estimates assume that monitoring frequency is
dropped to four visits per year, lot testing is done twice per year
and can be done in a lab in Kampala (rather than shipping
internationally) and that administrative duties can be spread over
more shops. Under this scenario, the cost per test falls to US$1.02.
The last cost estimate assumes that monitoring is done twice per
year, that the price of RDTs charged by the manufacturer is 25%
lower (reduced from US$0.69 to US$0.52 per test) and that shops
contribute somewhat to the program cost by paying for their own
food at training and by paying for the gloves that must be used
with the RDTs. Under this scenario, the cost per test distributed
through the program falls to US$0.59.
Discussion
Overall, the results from this study suggest that it is feasible to
distribute RDTs through the retail sector. All but one shop passed
the training and compliance rates at monitoring visits were very
high. Further, the majority of shops chose to continue stocking
RDTs after the first free box ran out. Results from this study
suggest, however, that there is significant heterogeneity in the
desire to sell RDTs on the part of shops. Some shops
enthusiastically adopted RDTs and promoted them to customers
while others sold them only rarely or not at all. The reasons for
heterogeneity are unclear – it is not known whether the differences
Table 4. RDT Sales by Month.
Boxes sold RDTs sold Fraction of Shops Purchasing Any RDTs Fevers per capita and month
July 47 1880 0.207 0.176
August 52 2080 0.261 0.165
September 59 2360 0.272 0.170
October 65 2600 0.315 0.203
November 57 2280 0.304 0.168
December 49 1960 0.239 0.181
doi:10.1371/journal.pone.0048296.t004
Figure 2. Trends in RDT Sales and Fevers.
doi:10.1371/journal.pone.0048296.g002
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This is a question that deserves more study. The fact that some
shops did not stock RDTs or sold them very infrequently suggests
there may be a limit to the scale of coverage one can reach
through a program such as the one explored here, at least in the
short-term. One possibility is that coverage could have been
increased if RDTs were available in smaller lots (the study
required a minimum purchase of a box of 40). Future research will
explore the impact of this intervention on community level
coverage with RDTs and health outcomes.
Despite the variation in stocking behavior, RDT pricing was
quite uniform, with 80% of shops reporting the same price of USH
1000. This price coincides with the price typically charged for
microscopy in private clinics in the area, and corresponds to a
100% markup, similar to the markup these shops charge for
commonly sold medicines. The household surveys confirmed that
USH 1000 was the most common price for RDTs, though
household responses displayed more variation, perhaps because of
recall bias or difficulty distinguishing between the cost of the RDT
and the cost of other components of treatment. This discrepancy
could also arise if shops charge patients different prices for RDTs,
but report to us only the price most commonly charged.
Interestingly, this estimate of the market price for RDTs is very
close to the estimated (stated) willingness to pay for RDTs (USH
1067) among drug shop customers in Uganda found in Hansen et
al. [41].
In addition to providing encouraging evidence that shops can
competently administer RDTs and have an incentive to sell them,
results from this study provide suggestive evidence that RDTs will
be used by shops and patients to guide treatment behavior in a
beneficial way. ACTs and other antimalarials were significantly
less likely to be purchased after a negative test result. This is
encouraging evidence that RDTs could help reduce the cost of
ACT subsidies or public support for malaria treatment more
generally. The results also show that antibiotic purchases were
higher for those testing negative than for those testing positive,
though not significantly so. Considering the high rate of positive
test results reported in the household survey—89% of patients
taking an RDT at a trained drug shop reported a positive result—
the results on treatment behavior conditional on test result should
be interpreted with caution. The high rate of positivity among
RDT takers may be interpreted as evidence that only patients with
very serious symptoms of malaria get tested, but likely also
represents a certain amount of recall bias among respondents.
Two other possibilities for this high rate are that people may not
have wanted to admit that they bought antimalarial medication
without having a positive test, or that shop owners falsely told
customers that they tested positive when they didn’t in order to get
them to buy antimalarials. When shop owners were asked about
the frequency of positive tests their recall was that about 60% of
tests were positive. The data collected did not allow to link
patient’s records to drug shop reports so that positivity rates
reported by shops and households could not directly be compared.
Even though the results presented here suggest that rolling out
RDTs in the retail sector is feasible, the overall reach of the
program appears limited at this stage. The household data
collected as part of this project suggest that 75% of fever patients
sought treatment outside of their household. Among those who
sought treatment, 53% did so at a drug shop (23% at a registered/
licensed shop and 30% at an unregistered shop). Even from those
fever patients who sought care at one of the trained shops, only
16% obtained a test. Overall, among fever patients sampled from
our study districts who sought care in the retail sector, only about
6% got tested in one of the trained shops. Of course, if RDTs were
sold to a higher fraction of customers at participating shops or if
unlicensed shops were able to sell RDTs as well, coverage rates
could increase substantially. Given that 45% of febrile illnesses in
the sample were treated at retail shops, the fraction of total fever
episodes that could be diagnosed through the retail sector is
potentially large.
The results presented in this paper should be interpreted as
short-term reactions to the introduction of RDTs on the part of
shops and patients. RDTs were not found in any of the program
shops at the time of the baseline interview and overall awareness of
Table 5. RDT Prices.
Household reports Shop reports
Price in USH N (%) N (%)
0 30 (6.30) 0 0.00
1–999 7 (1.47) 7 (2.99)
1000 263 (55.25) 184 (78.63)
1500 20 (4.20) 17 (7.26)
2000 89 (18.70) 20 (8.55)
2500 3 (0.63) 0 0.00
3000 23 (4.83) 1 (0.43)
.3000 10 (2.10) 0 0.00
Other/Don’t know 31 (6.51) 5 (2.14)
Notes: Data reflects self-reports by households and shops over the monitoring
period July to December 2011.
doi:10.1371/journal.pone.0048296.t005
Table 6. Compliance with RDT Storage and Waste Management.
Training Item Compliance Non-Compliance
N( % ) N ( % )
Is the storage area dry and cool? 267 85.58% 45 14.42%
Is the working surface flat? 308 98.72% 4 1.28%
Does the DSV dispose of all used cassettes immediately? 277 88.78% 35 11.22%
Keeps the sharps container closed when not in use? 308 98.72% 4 1.28%
Area around the drug shop clean from used RDT products? 310 99.36% 2 0.64%
Notes: Data is based on 312 completed monitoring visits between July and December 2011.
doi:10.1371/journal.pone.0048296.t006
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does not imply, however, that the study population was not
familiar with malaria testing more generally. During initial focus
groups, all participants indicated that they had heard of blood tests
(slides), and a large majority of subjects reported that they had
personally obtained blood tests at public health facilities. It is
possible that, with more time, stocking rates of RDTs would have
increased as shop owners became more comfortable with them
and as patient demand increased. Of course, it is also possible that
adoption was higher here than it would have been longer-term
because shops were experimenting with a new product that they
would later decide was not desirable or profitable. This project
involved an information/education campaign that was rolled out
after the study period explored in this paper. The role of this
campaign on adoption will be examined in future work.
It could also be the case that particular aspects of the training
program influenced adoption. Although the training program was
presented in informational and value-neutral terms, it is possible
that shop owners and other trainees considered the training to
indicate that use of RDTs was socially desirable. As a result, those
who participated in the study might have been more likely to sell
them than a shop owner who was simply provided with the RDTs
or one who had training from a company representative. On the
other hand, if a national RDT training program were to be rolled
out in shops, it is possible that more information on the social
value of RDTs and the shop staff’s responsibility to the community
could boost adoption rates above what is seen here. It is also
possible that our frequent monitoring of the drug shops increased
their likelihood of selling the tests above what it would be if there
was a lower level of supervision or no supervision at all.
Only licensed, registered drug shops were permitted to
participate in this study. In many rural areas, the majority of
shops available to consumers are not licensed. It is possible that the
shops in this study were better able to implement the use of RDTs
than the typical unlicensed shop would be. However, even if only
licensed shops were able to successfully use and market RDTs that
would greatly expand the availability of testing. There are several
reasons why it might be desirable to limit RDT scale up programs
to licensed shops, including the reduced monitoring burden from
fewer shops and the benefits of containing the program to more
Table 7. Compliance with RDT Administration Procedure.
Compliance Non-Compliance
N (%) N (%)
All supplies available before performing RDT 274 99.28% 2 0.72%
Expiry date on test packet checked 229 82.97% 47 17.03%
Administrator wears gloves properly 272 98.55% 4 1.45%
Opens packet and removes contents 269 97.46% 7 2.54%
Writes the patient’s name on the cassette 246 89.13% 30 10.87%
Cleans the patient’s 4
th finger with alcohol swab 275 99.64% 1 0.36%
Allows cleaned finger to dry before pricking 276 100.00% 0 0.00%
Opens lancet and pricks patient’s finger 276 100.00% 0 0.00%
Discards the lancet in sharps box after pricking 270 97.83% 6 2.17%
Use pipette to collect correct amount of blood 249 90.22% 27 9.78%
Uses pipette to place the drop of blood onto RDT 273 98.91% 3 1.09%
Discard pipette in the sharps box after placing blood on RDT 271 98.19% 5 1.81%
Places three drops of buffer into the round hole 275 99.64% 1 0.36%
Waits for 20 minutes before reading the results 266 96.38% 10 3.62%
Interprets the test results accurately 275 99.64% 1 0.36%
Records the results in registry 274 99.28% 2 0.72%
Disposes of cassette in sharps container 274 99.28% 2 0.72%
Notes: Based on 276 visits during which RDT administration was observed.
doi:10.1371/journal.pone.0048296.t007
Table 8. Compliance with RDT Administration Procedure over Time.
Average number of non-compliant behaviors Fraction of shops with any non-compliant behavior
August 0.792 0.479
September 0.406 0.275
October 0.500 0.396
November 0.371 0.314
December 0.308 0.231
Notes: Based on 276 visits during which RDT administration was observed.
doi:10.1371/journal.pone.0048296.t008
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unlicensed shops to participate could expand the program’s reach
so the benefits and risks of expanding to this cadre of drug shops
need to be weighed carefully.
While the study area was representative of rural and semi-urban
areas in Africa, it is possible that the results would not extend to
larger urban areas (where access to public facilities is higher). In
addition, these results may not represent areas of lower malaria
endemicity, as malaria treatment seeking is less frequent in places
where malaria burden is low, but the value of the test for
customers may be higher due to the reduced certainty about the
nature of the illness.
Despite several potential limitations, this study demonstrates
that a program distributing RDTs and providing training to drug
shop owners is a practical way to encourage the adoption of this
testing technology. The fact that unsubsidized RDTs were
available for sale in licensed pharmacies in Mbale and other
major cities, but that none of the program shops were selling them
at baseline, suggests that the subsidy and training are necessary for
promoting RDT sales in the retail sector. Overall this study
demonstrates that there is a demand for RDTs among shops and
patients and an ability among shop personnel to safely and
effectively administer RDTs. This suggests that the retail sector is a
viable channel for scaling up access to RDTs.
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